Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Health Care
  • Initiation
  • Long Ideas
  • Movers
  • Top Stories
  • Trading Ideas

Legend Biotech’s Cancer Drug, ‘The Most Attractive Product,’ Set For Growth: Analyst

By Priya Nigam
June 17, 12:15 PM
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

JNJ

Read More
2 minute read
  • Equities
  • General
  • News

Why EV Maker Polestar Automotive’s Shares Are Soaring Today

By Shivani Kumaresan
June 17, 12:09 PM
Shares of Polestar Automotive Holding are surging today after the company said it is expanding its global presence and enhancing its retail strategy to include both existing and new markets as its electric vehicle (EV) lineup grows.

PSNY

Read More
4 minute read
  • Analyst Ratings

The Analyst Verdict: Cloudflare In The Eyes Of 23 Experts

By Benzinga Insights
June 17, 12:01 PM
Throughout the last three months, 23 analysts have evaluated Cloudflare (NYSE:NET), offering a diverse set of opinions from…

NET

Read More
4 minute read
  • Analyst Ratings

4 Analysts Have This To Say About PagSeguro Digital

By Benzinga Insights
June 17, 12:00 PM
4 analysts have shared their evaluations of PagSeguro Digital (NYSE:PAGS) during the recent three months, expressing a mix…

PAGS

Read More
3 minute read
  • Analyst Ratings

Beyond The Numbers: 8 Analysts Discuss Palantir Technologies Stock

By Benzinga Insights
June 17, 12:00 PM
During the last three months, 8 analysts shared their evaluations of Palantir Technologies (NYSE:PLTR), revealing diverse outlooks from…

PLTR

Read More
3 minute read
  • Analyst Ratings

Analyst Expectations For Citigroup’s Future

By Benzinga Insights
June 17, 12:00 PM
Citigroup (NYSE:C) has been analyzed by 9 analysts in the last three months, revealing a diverse range of…

C

Read More
4 minute read
  • Analyst Ratings

6 Analysts Assess AG Mortgage IT: What You Need To Know

By Benzinga Insights
June 17, 12:00 PM
AG Mortgage IT (NYSE:MITT) has been analyzed by 6 analysts in the last three months, revealing a diverse…

MITT

Read More
3 minute read
  • Analyst Ratings

Critical Insights From Southwest Airlines Analyst Ratings: What You Need To Know

By Benzinga Insights
June 17, 12:00 PM
12 analysts have expressed a variety of opinions on Southwest Airlines (NYSE:LUV) over the past quarter, offering a…

LUV

Read More
3 minute read
  • Top Stories
  • Trading Ideas

GameStop, AMC, Tesla: Expert Sizes Up Short Interest In 3 Favorite Retail Investor Stocks

By Chris Katje
June 17, 12:00 PM
An update from S3 Partners shows short interest in GameStop, AMC and Tesla remaining high in 2024.

AMC

Read More
2 minute read
  • Equities
  • News

What’s Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?

By Vandana Singh
June 17, 11:47 AM
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies

AZN

Posts pagination

Previous 1 … 87 88 89 … 19,074 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service